Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 2Rectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 7Nivolumab 6pembrolizumab 4lenvatinib 3cabozantinib 3Axitinib 3vorolanib 2fludarabine 2anlotinib 2Sunitinib 2Nephrectomy 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Cyclophosphamide 2Biopsy 2toripalimab 1tivozanib 1sintilimab 1pazopanib 1fludarabine phosphate 1enzalutamide 1cemiplimab 1bemarituzumab 1belzutifan 1balstilimab 1atezolizumab 1abiraterone 1Zoledronic Acid 1Saline Solution 1Rubidium-82 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Renal Cell × balstilimab × Clear all
NCT07516366 2026-05-15

Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
16 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡